Cidara Therapeutics has successfully secured up to $339 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of its non-vaccine flu preventative candidate. This significant financial backing will primarily facilitate the establishment of U.S. manufacturing capabilities for the candidate, which is poised to address critical gaps in flu prevention.
The funding underscores the increasing recognition of the need for innovative approaches to influenza prevention, particularly in light of evolving viral strains and vaccine hesitancy. By investing in domestic manufacturing, Cidara aims to enhance the accessibility and reliability of its product, potentially positioning itself as a leader in the flu therapeutics market. The additional funding options tied to further clinical studies reflect BARDA’s commitment to advancing public health initiatives and ensuring readiness for future influenza outbreaks.
Start your 7-day trial and see what the database can do →
